BioWorld

Feb. 21, 2002

IDEC Gains Zevalin Approval For Non-Hodgkin’s Lymphoma

IDEC Pharmaceuticals Corp. received FDA approval of Zevalin to treat non-Hodgkin’s lymphoma and is poised to introduce the first radioimmunotherapy to the United States. (BioWorld Today) Read More

Fresh From Mergers, Buyouts, CEOs Mull Boons And Pitfalls

Pseudomonas aeruginosa, Lethal Cystic Fibrosis Scourge, Trades Surprise Blows With Scientists

Avant Dropping TP10 Following Phase II Failure; Stock Tumbles

Other News To Note

Bush Might Have Final Say On Biotech’s Role In Bioterrorism

Anadys, Structural GenomiX Form Antibacterials Alliance

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...